Lv4
528 积分 2022-09-07 加入
Post-Progression treatment options after CDK4/6 inhibitors in hormone Receptor-Positive HER2-Negative metastatic breast cancer
4天前
已完结
FDA approves 100th small-molecule kinase inhibitor
5天前
已关闭
In vivo chimeric antigen receptor (CAR)-T cell therapy
14天前
已完结
Synthetic lethality in cancer drug discovery: challenges and opportunities
14天前
已完结
Induced proximity-based therapeutic modalities
14天前
已完结
ANGPTL3/8: one target, multiple lipid disorders
14天前
已完结
Targeting the Hippo pathway in cancer
14天前
已完结
Cancer cachexia contender enters first pivotal trial
21天前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
1个月前
已完结
Rethinking TREM2 as a target for Alzheimer’s disease after the INVOKE-2 trial failure
1个月前
已完结
皖公网安备34019202002308
